An Indian company has plans to begin commercial production of a sweetener to rival Tate & Lyle’s sucralose brand Splenda in 14 months, according to a report today.
Go deeper with GlobalData
Pharmed Medicare president Sundeep Aurora told Dow Jones newswires that the company is currently making trial products. The plan is to produce 1,000 tonnes of the sweetener in its first phase in just over a year’s time.
He added that Pharmed is in talks with several possible customers globally.
